Citius Oncology Reports Accelerating LYMPHIR Demand as Institutional…

Event summary

Citius Oncology reported $7.1 million in revenue for the first nine months of fiscal 2026, driven by accelerating institutional demand for LYMPHIR.
Institutional vial orders grew 31% sequentially, with 44 institutions prescribing and ordering LYMPHIR since its launch.
The company expanded its commercial organization to nationwide coverage in August, adding 29 field-based professionals and medical science liaisons.
Phase 1 data for LYMPHIR in combination settings showed promising results in recurrent or refractory gynecologic cancers and DLBCL.

The big picture

Citius Oncology's strong institutional demand for LYMPHIR reflects growing acceptance in the CTCL market, which management estimates exceeds $400 million. The company's strategic focus on expanding its commercial footprint and exploring combination therapies positions it to capitalize on broader oncology trends. However, sustaining revenue growth and managing operational costs will be critical as it navigates the competitive landscape.

What we're watching

Commercial Execution: Whether Citius Oncology can sustain the momentum in institutional adoption and formulary inclusion at priority treatment centers.
Clinical Expansion: The pace at which investigator-initiated studies will advance LYMPHIR's potential in combination regimens beyond CTCL.
Financial Stability: How the company will manage its cash position and funding needs to support continued growth and commercialization efforts.